Compare IDEXX Laboratories, Inc. (IDXX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Trade Desk Inc — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Trade Desk Inc trades at $18.18 (market cap $8.76B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.1× Trade Desk Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | TTD | |
|---|---|---|
Market Cap | $44.48B | $8.76B |
Sector | Health | Technology |
52-Week High | $766.68 | $89.76 |
52-Week Low | $520.87 | $17.33 |
Enterprise Value | $45.38B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
The Trade Desk (TTD) trades at $18.68, down 76% year-to-date amid slowing revenue growth and executive turnover. Recent technical signals are bearish, with moving averages indicating selling pressure, while fundamentals show strong profitability with a 77.83% gross margin and 14.57% net margin. The company has beaten earnings estimates in two of the last three quarters but missed Q1 2026 expectations. Recent news highlights key executive appointments and a resolved dispute with Publicis Groupe.
Outlook: TTD faces headwinds from competitive pressure and growth deceleration, but current valuation at 21.13x P/E may attract value investors. Risks include market share loss to larger rivals and execution challenges. Analyst consensus price target of $25.23 suggests 35% upside potential, though sentiment remains divided with nearly equal buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
